Lanreotide Zentiva

Lanreotide, the active ingredient in Lanreotide Zentiva, is a somatostatin analog presented as a subcutaneous formulation for injection use. It treats acromegaly and neuroendocrine tumors in adult patients. GNH USA supplies Lanreotide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lanreotide is a somatostatin analog used in endocrine disorders that involve excess hormone secretion. - Acromegaly: normalises elevated growth hormone levels and reduces associated tissue overgrowth. - Neuroendocrine tumors: controls hormone‑related symptoms and can slow tumor progression. - Carcinoid syndrome: alleviates flushing, diarrhoea and other secretory manifestations linked to functional neuroendocrine tumours.

Lanreotide may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site pain or erythema - Nausea or abdominal discomfort - Diarrhoea or constipation - Headache - Hyperglycaemia or altered glucose tolerance - Gallstone formation

Serious or Rare Side Effects: - Acute pancreatitis - Severe hyperglycaemia requiring medical intervention - Anaphylactic or severe allergic reactions - Cardiac arrhythmias - Pituitary apoplexy (rare in acromegaly patients)

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Pregnancy: safety not established; use only if benefit outweighs potential risk. - Renal impairment: assess renal function and adjust monitoring. - Diabetes or impaired glucose tolerance: monitor blood glucose closely. - Gallbladder disease: watch for gallstone development during treatment. - Concomitant medications: review for possible interactions before prescribing. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Co‑administration with other somatostatin analogues: risk of excessive hormonal suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lanreotide exposure.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: possible need for dose adjustment due to altered glucose control. - Diuretics: monitor electrolyte balance, especially potassium. - Anticoagulants: observe for changes in bleeding tendency. - Oral contraceptives: hormonal efficacy may be reduced; consider alternative contraception.